Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.58 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19848595 | 0.86 | HCAR3 (0.46) | HCAR3KMT2AKDM4EARGRM2 | |
| SCHEMBL19911472 | 0.80 | HCAR3 (0.59) | HCAR3KCNMA1ALDH1A1PKMMEN1 | |
| SCHEMBL19848185 | 0.79 | PKM (0.61) | HCAR3KCNMA1ALDH1A1PKMMEN1 | |
| SCHEMBL21669989 | 0.79 | HCAR3 (0.58) | HCAR3KCNMA1ALDH1A1PKMMEN1 | |
| SCHEMBL21445739 | 0.79 | HCAR3 (0.58) | HCAR3ALDH1A1PKMMEN1KMT2A | |
| SCHEMBL19911588 | 0.79 | HCAR3 (0.58) | HCAR3ALDH1A1PKMMEN1KMT2A | |
| SCHEMBL19911502 | 0.76 | HCAR3 (0.55) | HCAR3ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL18323574 | 0.76 | HCAR3 (0.54) | HCAR3KCNMA1ALDH1A1MEN1KMT2A | |
| SCHEMBL31349698 | 0.75 | HCAR3 (0.54) | HCAR3ALDH1A1KMT2AHTTKDM4E | |
| SCHEMBL19915949 | 0.75 | HCAR3 (0.54) | HCAR3ALDH1A1KMT2AHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-08-25 | — | — | US | disclosed |
| EP-3467930-B1 | NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY | ASAHI CHEMICAL IND (JP) | 2020-05-13 | — | — | EP | disclosed |
| EP-3467930-A1 | NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2019-04-10 | — | — | EP | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
| EP-3279997-A1 | NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY | Asahi Kasei Kabushiki Kaisha (JP) | 2018-02-07 | — | — | EP | disclosed |
| US-9522910-B2 | Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon | Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) | 2016-12-20 | — | — | US | disclosed |
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU "FUSION PHARMA" (RU) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | BPTF, BRD4, KCNN2 | HCAR3 4636/4885KCNMA1 525/4885ALDH1A1 3497/4885 |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | BPTF, BRD4, KCNN2 | HCAR3 4636/4885KCNMA1 525/4885ALDH1A1 3497/4885 |
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | ABL1, ABL2, MAP3K6 | HCAR3 4451/4885KCNMA1 1606/4885ALDH1A1 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.